-
Mashup Score: 0Dupilumab Associated with Improvements in Pediatric Asthma - 4 year(s) ago
The drug has potential to be best-in-class treatment option for children aged 6-11 years with uncontrolled moderate-to-severe asthma.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Add-On Dupilumab Significantly Clears Pediatric Eczema Skin - 4 year(s) ago
New pivotal phase 3 findings support an upcoming sBLA for the IL4 and IL13-targeting agent.
Source: HCPLive®Categories: General Medicine NewsTweet-
"This is a patient group that needs it so much, that I’m sure our #FDA will help these families out." Dr. Paller of @NUFeinbergMed discusses #Dupixent for pediatric atopic dermatitis in a new #DocTalk podcast. https://t.co/VkvKy1HkBx
-
-
Mashup Score: 0
Dupixent combined with standard-of-care topical corticosteroids significantly improved disease signs, symptoms and health-related quality of life in children with AD.
Source: Practical DermatologyCategories: DermatologyTweet-
Dupixent showed significant improvement in severe #atopicdermatitis for children aged 6 to 11 Years. In a Phase 3 study, #Dupixent combined with topical corticosteroids significantly improved disease signs, symptoms & health-related QoL in children. https://t.co/1Tc8zNBJuq https://t.co/g8XPEuQmKa
-
"#Dupixent is the only biologic shown in a controlled Phase 3 trial to improve lung function in children, which is generally consistent with results seen in the adolescent and adult trials." #asthma https://t.co/i7D2yFMITa